title: Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
abstract: We have analysed the prognostic information for survival of presenting features in an unselected series of 394 myeloma patients. 15 variables with significant prognostic information were identified, among these were some not previously or only recently reported: serum levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), C-terminal cross-linked telopeptide of collagen I (ICTP) and soluble interleukin-6 receptor (sIL-6R). In a multivariate Cox analysis six variables were significantly and independently associated with poor survival: high age, low W.H.O.-performance status (PS), high serum levels of calcium, beta-2-microglobulin (beta-2M), IL-6 and sIL-6R. A risk score formed to predict survival for each percentile of the patient population allowed an efficient separation of prognostic groups. The discriminating power of the model compared favourably with three other previously published staging systems applied to the study population. Exclusion of IL-6 and sIL-6R from the model only marginally decreased the efficacy of the separation. The predictive value of some variables (sIL-6R, beta-2M and W.H.O.-PS) decreased significantly over time. We conclude that formation of a risk score based on independent variables is an efficient way to separate prognostic groups, that the contribution of new and not easily available parameters should be thoroughly evaluated before inclusion in prognostic models for clinical use and that the predictive value of parameters may decrease over time.
authors.affiliation: Department of Medicine, Malmö University Hospital, Malmö, Sweden. ingemar.turesson@medforsk.mas.lu.se
authors.forename: I
authors.initials: I
authors.lastname: Turesson
authors.forename: N
authors.initials: N
authors.lastname: Abildgaard
authors.forename: T
authors.initials: T
authors.lastname: Ahlgren
authors.forename: I
authors.initials: I
authors.lastname: Dahl
authors.forename: E
authors.initials: E
authors.lastname: Holmberg
authors.forename: M
authors.initials: M
authors.lastname: Hjorth
authors.forename: J L
authors.initials: JL
authors.lastname: Nielsen
authors.forename: A
authors.initials: A
authors.lastname: Odén
authors.forename: C
authors.initials: C
authors.lastname: Seidel
authors.forename: A
authors.initials: A
authors.lastname: Waage
authors.forename: J
authors.initials: J
authors.lastname: Westin
authors.forename: F
authors.initials: F
authors.lastname: Wislöff
mesh_terms: D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D009101:Multiple Myeloma / Q000097:blood / Q000628:therapy*; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000097:blood; D012307:Risk Factors; D016019:Survival Analysis; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D001613:beta 2-Microglobulin